Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | YEATS4 | O95619 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PLD2 | O14939 | 16/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 16/20 | 0.46 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.44 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439012 | 0.93 | USP2 (0.63) | USP2ALDH1A1LMNAYEATS4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4440079 | 0.89 | YEATS4 (0.59) | USP2ALDH1A1LMNAYEATS4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL15574954 | 0.84 | OPRM1 (0.48) | USP2ALDH1A1LMNAKCNH2PLD2 | |
| Trifluoroacetic Acid SCHEMBL4440191 | 0.83 | PGR (0.40) | USP2ALDH1A1LMNAKCNH2PLD2 | |
| Trifluoroacetic Acid SCHEMBL15575354 | 0.81 | OPRM1 (0.51) | USP2ALDH1A1LMNAPLD2PLD1 | |
| SCHEMBL3134355 | 0.81 | USP2 (0.58) | USP2ALDH1A1LMNAYEATS4KCNH2 | |
| SCHEMBL14008572 | 0.81 | YEATS4 (0.66) | USP2ALDH1A1LMNAYEATS4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4436898 | 0.80 | OPRM1 (0.52) | USP2ALDH1A1LMNAKCNH2PLD2 | |
| SCHEMBL4434705 | 0.80 | USP2 (0.57) | USP2ALDH1A1LMNAYEATS4KCNH2 | |
| SCHEMBL13153966 | 0.79 | ALDH1A1 (0.57) | USP2ALDH1A1LMNAYEATS4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | USP2 896/4885ALDH1A1 2622/4885LMNA 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.